Prostate Cancer Training (PCaT): 3. Discussing with patients
Learning Objective: At the end of this module, you will learn how to assess the risk of prostate cancer in different patients and discuss screening for prostate cancer with patients using the shared decision making approach.
Prostate Cancer Training (PCaT): 3. Discussing with patients
Here are some references if you like to have further reading:
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89. doi:10.14740/wjon1191
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
Aziah AM, Hashimah B, Nirmal K, Siti Zubaidah AR, Puteri NA, Nabihah A, Sukumaran R, Balqis B, Nadia SM, Sharifah SS. Malaysia National Cancer Registry Report (MNCR) 2012-2016. Putrajaya, Ministry of Health Malaysia, 2019.
National Cancer Institute. Malaysian Study On Cancer Survival (MySCan). Putrajaya, Ministry of Health Malaysia, 2018.
Ng K, Smith S, Shamash J. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. Oncol Ther. 2020;8(2):209-230. doi:10.1007/s40487-020-00119-z
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter [published correction appears in N Engl J Med. 2004 Sep 30;351(14):1470]. N Engl J Med. 2004;350(22):2239-2246. doi:10.1056/NEJMoa031918
U.S. Preventive Services Task Force., & United States. (2018). U.S. Preventive Services Task Force (USPSTF): Screening for Prostate Cancer. Rockville, MD: U.S. Dept. of Health & Human Services, Agency for Healthcare Research and Quality. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/prostate-cancer-screening. Accessed 10 Nov 2021.
Schrager S, Phillips G, Burnside E. A simple approach to shared decision making in cancer screeening. Family Practice Management, 2017;24(3):5-10.
Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651-661. doi:10.1016/s0277-9536(99)00145-8
Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. Draft clinical practice guidelines for PSA testing and early management of test-detected prostate cancer. Prostate Cancer Foundation of Australia and Cancer Council Australia, Sydney (2016). Prostate Cancer Foundation of Australia and Cancer Council Australia.
Babjuk M, Burger M, Comperat E, Gontero P, Mostafid AH, Palou J. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. EAU Guidelines Office, Arnhem, The Netherlands. 2020.
Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860-864.
